A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Trial Details

NCT ID
NCT04895709
Phase
PHASE1 / PHASE2
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • BMS-986340
  • BMS-936558-01
  • Docetaxel
Locations (sample)
  • Clovis, California, United States|36.82523,-119.70292
  • Los Angeles, California, United States|34.05223,-118.24368
  • Newport Beach, California, United States|33.61891,-117.92895
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis.
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, …
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • Radiographically documented progressive disease on or after the most recent therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →